Pacific Biosciences of California(US:PACB) ZACKSยท2025-10-06 23:16Company Performance - Pacific Biosciences of California (PACB) ended the recent trading session at $1.52, showing a +2.01% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.37% [1] - Prior to today's trading, shares of Pacific Biosciences had gained 17.32%, significantly exceeding the Medical sector's gain of 5.9% and the S&P 500's gain of 4.26% [1] Earnings Forecast - The upcoming earnings disclosure is anticipated to show an EPS of -$0.16, reflecting a 5.88% growth compared to the same quarter last year [2] - Revenue is forecasted to be $40.38 million, indicating a 1.03% growth compared to the corresponding quarter of the previous year [2] Full Year Estimates - For the full year, analysts expect earnings of -$0.6 per share and revenue of $158.75 million, representing changes of +27.71% and +3.07% respectively from last year [3] Analyst Sentiment - Recent adjustments to analyst estimates for Pacific Biosciences are indicative of shifting short-term business dynamics, with upward revisions reflecting analysts' positive outlook on the company's operations and profit generation capabilities [4] - The Zacks Rank system, which assesses these estimate changes, currently ranks Pacific Biosciences as 3 (Hold) [6] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, holds a Zacks Industry Rank of 144, placing it in the bottom 42% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]